Barinthus Biotherapeutics plc
BRNS · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 1,766.5% | -98.2% | 16,580.2% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 100% | 100% | 100% | 100% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $0 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -454.1% | -10,463.1% | -9% | -16,873.5% |
| Other Income/Exp. Net | $0 | $0 | $0 | -$0 |
| Pre-Tax Income | -$0 | -$0 | $0 | -$0 |
| Tax Expense | -$0 | -$0 | -$0 | -$0 |
| Net Income | -$0 | -$0 | $0 | -$0 |
| % Margin | -408% | -9,145.5% | 11.9% | -18,979.5% |
| EPS | -1.55 | -1.91 | 0.14 | -1.37 |
| % Growth | 18.8% | -1,464.3% | 110.2% | – |
| EPS Diluted | -1.55 | -1.91 | 0.14 | -1.37 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$0 | -$0 | $0 | -$0 |
| % Margin | -369.9% | -8,861% | 11.6% | -17,861.9% |